In PCa, the PI3K/AKT pathway is one of the common genomically altered pathways in mCRPC patients due to PTEN loss and maybe a potential target for alternative therapy for PCa that is not sensitive to anti-androgen therapy. This evidence concerns the gene AKT1 and posterior cortical atrophy.